Develop Market-Entry And Market Expansion Strategies Of Growth Hormone Deficiency Market: Opportunity Analysis and Forecast to 2026
"The
Latest Research Report OpportunityAnalyzer: Growth Hormone Deficiency
- Opportunity Analysis and Forecasts to 2026 provides information on
pricing, market analysis, shares, forecast, and company profiles for
key industry participants. - MarketResearchReports.biz"
About
Growth Hormone Deficiency Market
Growth hormone deficiency (GHD) is
a rare endocrine disorder characterized by inadequate secretion of
growth hormone (GH) from the anterior pituitary gland. It is a
heterogeneous disorder that may present in childhood (pediatric GHD)
or later in adult life (adult GHD). Reduced GH secretion
predominantly results in stunted linear growth in children;
therefore, the standard-of-care GH replacement therapy serves to
normalize height in children. Adults with GHD generally demonstrate
biochemical abnormalities, which can also be successfully treated
with recombinant GH. GlobalData estimates the 2016 sales for GHD at
approximately $1.42 billion across the 7MM covered in this report.
The market will grow moderately at a CAGR of 3.9% during the 10-year
forecast period, generating sales of approximately $2.08 billion at
the end of 2026. The US market is expected to grow the fastest of the
three regions, recording a CAGR of 4.4% and generating around 69% of
global sales in 2026. This growth will be driven primarily by the
highly anticipated arrivals of the long-acting GHs and the resultant
increase in compliance with and adherence to therapy. Although the
more convenient long-acting GHs are expected to markedly change the
GHD treatment landscape, and eventually replace daily GHs, market
growth will be restricted by the continued negotiations between
distributers and payers, which is expected to keep the prices of
these new drugs at bay.
Key Questions Answered
Overall, the greatest unmet need
in the GHD space is the issue with treatment adherence and
compliance. There are other prominent unmet needs highlighted by the
Key Opinion Leaders (KOLs). What are these? Will the pipeline drugs
fulfil these unmet needs of the market?
Get
Sample copy of this Report @
https://www.marketresearchreports.biz/sample/sample/1142783
The 10-year forecast period will
mark the launch of four pipeline long-acting GH drugs. How will the
sales of the existing drugs be impacted? Which of the pipeline drugs
will have the highest peak sales at the highest CAGR, and why?
What are the roles of payers in
this highly competitive disease space? How does this affect market
shares of the GH brands? What are the chances of reimbursement for
the long-acting GH drugs in pipeline?
Scope
Overview of GHD, including
epidemiology, etiology, pathophysiology, symptoms, diagnosis, and
treatment guidelines.
Annualized GHD therapeutics market
revenue, annual cost of therapy and treatment usage pattern data from
2016 and forecast for ten years to 2026.
Key topics covered include
strategic competitor assessment, market characterization, unmet
needs, clinical trial mapping and implications for the GHD
therapeutics market.
Pipeline analysis: comprehensive
data split across different phases, emerging novel trends under
development, and detailed analysis of late-stage pipeline drugs.
Analysis of the current and future
market competition in the global GHD therapeutics market. Insightful
review of the key industry drivers, restraints and challenges. Each
trend is independently researched to provide qualitative analysis of
its implications.
Reasons to buy
The report will enable you to:
Develop and design your
in-licensing and out-licensing strategies through a review of
pipeline products and technologies, and by identifying the companies
with the most robust pipeline. Additionally a list of acquisition
targets included in the pipeline product company list.
Develop business strategies by
understanding the trends shaping and driving the global GHD
therapeutics market.
Drive revenues by understanding
the key trends, innovative products and technologies, market
segments, and companies likely to impact the global GHD therapeutics
market in future.
Formulate effective sales and
marketing strategies by understanding the competitive landscape and
by analysing the performance of various competitors.
Identify emerging players with
potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
Track drug sales in the 7MM GHD
therapeutics market from 2016-2026.
Organize your sales and marketing
efforts by identifying the market categories and segments that
present maximum opportunities for consolidations, investments and
strategic partnerships.
Companies mentioned
Novo Nordisk
Pfizer
Genentech/Roche
Ipsen SA
Eli Lilly
EMD Serono
Ferring
JCR Pharmaceuticals
Sandoz
LG Life Sciences
Biopartners GmbH
OPKO Health
Versartis Inc.
Ascendis
Send
An Enquiry Request @
https://www.marketresearchreports.biz/sample/enquiry/1142783
Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Growth Hormone Deficiency:
Executive Summary
2.1 GHD Market Will Exhibit
Moderate Growth Between 2016 and 2026
2.2 Long-Acting Growth Hormones
Will Fuel Market Growth and Improve the Treatment Landscape for GHD
Patients
2.3 Payer Preferences Heavily
Influence Market Shares of GH Drugs in the US
2.4 Disease Awareness and
Stringent Regulatory and Insurance Policies Are Major Challenges in
the GHD Market
2.5 Opportunities for New Entrants
After the Launch of Long-Acting GHs Will Be Low During the Forecast
Period
2.6 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Symptoms
4.3 Prognosis
4.4 Quality of Life
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 GHD in children
5.5 GHD in adults
5.6 Forecast Methodology
5.6.1 Sources
5.6.2 Forecast Assumptions and
Methods
5.7 Epidemiological Forecast for
GHD (2016-2026)
5.7.1 Diagnosed Prevalent Cases of
GHD
5.7.2 Age-Specific Diagnosed
Prevalent Cases of GHD
5.7.3 Sex-Specific Diagnosed
Prevalent Cases of GHD
5.7.4 Idiopathic and Organic GHD
in Children
5.7.5 Congenital and Acquired GHD
Out of Organic GHD in Children
5.7.6 Idiopathic and Acquired GHD
in Adults
5.7.7 Onset Timing
5.8 Discussion
5.8.1 Epidemiological Forecast
Insight
5.8.2 Limitations of Analysis
5.8.3 Strengths of the Analysis
6 Current Treatment Options
6.1 Overview
6.2 Diagnosis and Treatment
6.2.1 Diagnosis
6.2.2 Treatment Guidelines and
Leading Prescribed Drugs
6.3 Clinical Practice
6.4 Market Access and
Reimbursement
6.5 Product Profiles –
Recombinant Human Growth Hormones
6.5.1 Overview
6.5.2 Genotropin
6.5.3 Humatrope
6.5.4 Norditropin
6.5.5 Nutropin AQ
6.5.6 Saizen
6.5.7 Zomacton/Growject
6.5.8 Omnitrope
6.5.9 Valtropin Biosimilar
6.5.10 Efficacy
6.5.11 Safety
6.5.12 SWOT Analysis
6.6 Product Profiles –
Long-Acting Recombinant Human Growth Hormones
6.6.1 Somatropin Biopartners
(LB-03002)
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
Comments
Post a Comment